#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic kidney disease Krabbe's disease Uveal melanoma Cervix carcinoma Necrotising enterocolitis neonatal Infective uveitis Ocular lymphoma Brain stem glioma Neuropathic arthropathy Myelodysplastic syndrome Cold type haemolytic anaemia Osteomyelitis Fatty acid oxidation disorder Oropharyngeal squamous cell carcinoma Eosinophilic oesophagitis More trials…

    Learn about Rare Diseases

    Carcinoid syndrome – Basic Information Pelizaeus-Merzbacher disease – Basic Information Nephrotic syndrome – Basic Information Hereditary motor and sensory neuropathy – Treatment Cholangitis sclerosing – Trials in Disease Optic glioma Toxic epidermal necrolysis – Treatment Hereditary angioedema – Life with Disease Acquired haemophilia – Trials in Disease Retinitis pigmentosa – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cat Epithelia POLYMYXIN B SULFATE Pirtobrutinib Estradiol Osilodrostat Bendamustine Hydrochloride Mitapivat Dapirolizumab Pegol TUVATEXIB Alendronic Acid Zibotentan Mbf-015 Azd8205 Digoxin Immune Fab (Ovine) Balcinrenone Doxazosin Poa Pratensis Pollen Extract Ofloxacin Hydrochloride DAPIGLUTIDE Fluorescein Sodium More therapies…

    Learn about Your Condition

    Cartilage injury Chronic lymphocytic leukaemia Irritable bowel syndrome Duchenne muscular dystrophy Respiratory tract infection Ovarian cancer stage III Gastric cancer Alopecia areata Malignant glioma Chronic kidney disease Necrotising myositis Adenocarcinoma Incontinence Dystonic tremor Anal fissure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Azienda Ospedaliera di Padova

Azienda Ospedaliera di Padova

Via Nicolo' Giustiniani 2, Padua, 35128, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

    Not recruiting

    3 1 1
    Investigated Diseases:
    • IgA nephropathy
    Investigated Drugs:
    • Ravulizumab
    Austria Belgium Czechia France Germany Greece +6

  • Study on the Safety and Effectiveness of Polatuzumab Vedotin with Rituximab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma refractory
    Investigated Drugs:
    • Polatuzumab Vedotin
    • Gemcitabine Hydrochloride
    • Oxaliplatin
    France Germany Greece Italy Spain

  • Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Blinatumomab
    • Crisantaspase
    • Daunorubicin Hydrochloride
    Austria Czechia Germany Italy Slovakia

  • Comparison of Nilotinib versus Imatinib treatment in newly diagnosed chronic myeloid leukemia patients to achieve treatment-free remission

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Imatinib
    • Nilotinib
    Italy The Netherlands

  • Study on the Safety and Effectiveness of AMX0035 (Phenylbutyrate and Ursodoxicoltaurine) for Adults with Amyotrophic Lateral Sclerosis (ALS)

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Amyotrophic lateral sclerosis
    Investigated Drugs:
    • Phenylbutyrate
    • Ursodoxicoltaurine
    Belgium France Germany Ireland Italy The Netherlands +4

  • Study on the Effectiveness and Safety of Guselkumab for Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    4 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Guselkumab
    Belgium Bulgaria Czechia France Germany Hungary +7

  • Study on the Safety and Effectiveness of Crinecerfont for Adults with Classic Congenital Adrenal Hyperplasia

    Not recruiting

    3 1
    Investigated Diseases:
    • Adrenogenital syndrome
    Investigated Drugs:
    • Crinecerfont
    Austria Belgium Bulgaria Czechia France Germany +6

  • Study of Lu AG13909 in Adults with Cushing’s Disease to Evaluate Safety and Effectiveness

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Pituitary-dependent Cushing’s syndrome
    Investigated Drugs:
    • Ag13909
    France Hungary Italy Poland Romania Spain

  • Study to Evaluate mRNA-3210 for Safety and Tolerability in Patients with Phenylketonuria

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Phenylketonuria
    Investigated Drugs:
    • Buclizine Hydrochloride
    • Codeine Phosphate
    • Fexofenadine
    France Italy Spain

  • Study on Deucrictibant and Icatibant for Treating Hereditary Angioedema Attacks in Adolescents and Adults

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Deucrictibant
    • Icatibant
    Austria Bulgaria Czechia France Germany Hungary +8
Previous Page
1 … 34 35 36 37 38 … 41
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!